CM
NKTR icon

Caption Management’s Nektar Therapeutics NKTR Stock Holding History

Caption Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8M Buy
150,000
+75,000
+100% +$4.27M 0.06% 309
2025
Q4 		$3.17M Sell
75,000
-2,500
-3% -$140K 0.02% 670
2025
Q3 		$4.41M Buy
+77,500
New +$2.57M 0.03% 535
2022
Q2 		– Sell
-10,927
Closed -$883K – 1701
2022
Q1 		$883K Buy
10,927
+9,260
+555% +$1.37M 0.01% 1019
2021
Q4 		$338K Buy
+1,667
New +$362K ﹤0.01% 1342
2021
Q3 		– Sell
-2,000
Closed -$514K – 1694
2021
Q2 		$514K Hold
2,000
– – 0.01% 1035
2021
Q1 		$600K Buy
+2,000
New +$622K 0.01% 777
2020
Q4 		– Sell
-1,333
Closed -$331K – 1174
2020
Q3 		$331K Sell
1,333
-1,334
-50% -$420K 0.01% 841
2020
Q2 		$927K Buy
2,667
+467
+21% +$146K 0.03% 552
2020
Q1 		$588K Sell
2,200
-467
-18% -$144K 0.03% 510
2019
Q4 		$864K Buy
2,667
+1,334
+100% +$387K 0.03% 530
2019
Q3 		$365K Buy
+1,333
New +$489K 0.02% 526

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Caption Management's NKTR Position: Q1 2026 in Review

Caption Management sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 35,000 shares — an estimated $1.99M sold.

Caption Management first reported a position in NKTR in Q2 2018 and held it in 11 quarters. The position peaked at $1.48M in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Caption Management reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 35,000 Nektar Therapeutics shares in Q1 2026, an estimated $1.99M.
  • Caption Management first reported a position in Nektar Therapeutics in Q2 2018 and held it in 11 quarters.
  • Caption Management's Nektar Therapeutics position peaked at $1.48M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.